MCHR1 antagonist 2

MedChemExpress

®

Cat. No.:	HY-100321		
CAS No.:	863115-70-2		
Molecular Formula:	C ₂₃ H ₂₁ FN ₂ O ₅		
Molecular Weight:	424.42		
Target:	MCHR1 (GPR24); Potassium Channel		
Pathway:	GPCR/G Protein; Neuronal Signaling; Membrane Transporter/Ion Channel		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

SOLVENT & SOLUBILITY

In Vitro DMSO : 10 mg/mL (2 Preparing Stock Solutions	DMSO : 10 mg/mL (23.56 mM; ultrasonic and adjust pH to 6 with HCl)							
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg			
		1 mM	2.3562 mL	11.7808 mL	23.5616 mL			
	5 mM	0.4712 mL	2.3562 mL	4.7123 mL				
		10 mM	0.2356 mL	1.1781 mL	2.3562 mL			
	Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1 mg/mL (2.36 mM); Clear solution							
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1 mg/mL (2.36 mM); Clear solution							
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1 mg/mL (2.36 mM); Clear solution							

BIOLOGICALACTIVIT						
Description	MCHR1 antagonist 2 is an antagonist of melanin concentrating hormone receptor 1, with an IC ₅₀ of 65 nM; MCHR1 antagonist 2 also inhibits hERG, with an IC ₅₀ of 4.0 nM in IMR-32 cells ^[1] .					
IC ₅₀ & Target	IC50: 65 nM (melanin concentrating hormone receptor 1), 4.0 nM (hERG in IMR-32 cells) ^[1]					
In Vitro	MCHR1 antagonist 2 (Compound 30) is an antagonist of melanin concentrating hormone receptor 1, with an IC ₅₀ of 65 nM. MCHR1 antagonist 2 has inhibitory effects on Ca^{2+} flux, and hERG, with IC ₅₀ s of 196 ± 30 nM and 4.0 ± 0.8 nM, respectively, in					

F´

IMR-32 cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Lynch JK, et al. Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety. J Med Chem. 2006 Nov 2;49(22):6569-84.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA